Maslov L N, Barzakh E I, Krylatov A V, Brown S A, Oeltgen P R, Govindaswami M, Chernysheva G A, Solenkova N V, Lishmanov A Iu, Tsibul'nikov S Iu, Krieg T, Zhang E
Ross Fiziol Zh Im I M Sechenova. 2009 Jun;95(6):563-72.
The study aimed at investigation of the role of opioid receptor (OR) in regulation of cardiac tolerance to ischemia-reperfusion. Opioid receptor ligands and inhibitors were administered in vivo prior to coronary artery occlusion (45 min) and reperfusion (2 hrs). Occurring infraction size/area at risk (IS/AAR) ratio was determined. Pretreatment with the micro-OR agonists DAMGO and dermorphin H exerted no effect on the IS/AAR ratio. Activation of delta 1-OR by DPDPE did not alter cardiac tolerance in ischemia-reperfusion either. Pretreatment with the delta 2-OR agonists deltorphin D and deltorphin E or ORL1 receptor agonist nociceptin exerted no effect on the IS/AAR ratio. Stimulation of K-OR by selective agonists did not modify cardiac tolerance to ischemia-reperfusion. The delta 2-OR agonist deltorphin II significantly reduced the IS/AAR index. This effect was prevented by treatment with naltrexone, naloxone methiodide and the delta 2-OR antagonist naltriben but not by the delta 1-OR antagonist BNTX. The infarction-limiting effect of deltorphin II was also abolished by inhibition of protein kinase C (PKC) and mitochondrial Katp channels. Thus, the agonists of micro, delta 1, kappa, and ORL1 receptors in used doses did not affect cardiac tolerance in ischemia-reperfusion injury in vivo. The peripheral delta 2-OR activation induces infarction size reduction. Its infarction-reducing effect of deltorphin II is mediated via PKC activation and mitochondrial Katp, channel opening.
该研究旨在调查阿片受体(OR)在调节心脏对缺血再灌注耐受性中的作用。在冠状动脉闭塞(45分钟)和再灌注(2小时)之前,在体内给予阿片受体配体和抑制剂。测定梗死面积/危险面积(IS/AAR)比值。用微阿片受体激动剂DAMGO和皮啡肽H预处理对IS/AAR比值没有影响。DPDPE激活δ1-阿片受体也不会改变缺血再灌注时的心脏耐受性。用δ2-阿片受体激动剂强啡肽D和强啡肽E或孤啡肽受体激动剂孤啡肽预处理对IS/AAR比值没有影响。选择性激动剂刺激κ-阿片受体不会改变心脏对缺血再灌注的耐受性。δ2-阿片受体激动剂强啡肽II显著降低了IS/AAR指数。纳曲酮、甲硫氨酸纳洛酮和δ2-阿片受体拮抗剂纳曲本治疗可阻止这种作用,但δ1-阿片受体拮抗剂BNTX则不能。蛋白激酶C(PKC)和线粒体ATP敏感性钾通道(mitochondrial Katp channels)的抑制也消除了强啡肽II的梗死限制作用。因此,所用剂量的微阿片受体、δ1、κ和孤啡肽受体激动剂在体内不影响缺血再灌注损伤时的心脏耐受性。外周δ2-阿片受体激活可导致梗死面积减小。强啡肽II的梗死减小作用是通过PKC激活和线粒体ATP敏感性钾通道开放介导的。